Executive Leadership

James G. Wetrich, FACHE
Chief Executive Officer

Contact:
T: 817.488.7282
bigred@wetrichgroup.com

James G. Wetrich, FACHE, serves as the CEO of The Wetrich Group LLC and The Wetrich Group SCO LLC.

Wetrich is a leader in the health care advisory field and is influenced from more than 30 years of experience in leading successful business endeavors.

He has worked in a number of commercial capacities and has been involved in a wide variety of companies and entrepreneurial activities in the United States, Europe and Latin America. Wetrich has successfully launched several types of products, created successful partnerships, been involved in licensing deals and acquisitions and has served on a number of for-profit and not-for-profit boards, as well as advisory boards.


Wetrich spent the initial part of his career on the provider side of healthcare. He worked in hospital administration at Ochsner Hospital as vice president of the Metropolitan Hospital Council of New Orleans, and as vice president with Pitts Management Associates (PMA). During his time with David R. Pitts, FACHE, at PMA, he played an instrumental role in the development of the University Health System Consortium (UHC). Mr. Wetrich later joined UHC as the director of business development.

Wetrich left UHC and the provider side of the industry to join Abbott Laboratories as manager of corporate strategic planning. For four years he managed Abbott's largest customer, Novation. His responsibilities at Novation exceeded $1 billion and spanned all aspects of Abbott's businesses including diagnostics, hospital products, nutritional products and pharmaceuticals.

In 2001, Wetrich established The Wetrich Group to provide management consulting services to pharmaceutical, medical device and health care providers. From 2001-2006, The Wetrich Group served more than 40 clients including Abbott Laboratories, Dell, Roche Diagnostics, Novation, Terumo Medical Corporation and UHC.

In 2006, Mr. Wetrich joined Molnlycke Health Care where he initially served as president and general manager of the U.S. and Latin American wound care operations, and he was later promoted to president and general manager of the Americas. During his eight-year tenure at Molnlycke, the U.S. wound care organization experienced dramatic growth with sales increasing nearly eight fold and earnings increasing more than 20 times. In addition, the U.S. surgical organization was turned around and directed toward a more sustainable environment.

In 2014, Wetrich returned to The Wetrich Group LLC and shortly thereafter established The Wetrich Group SCO LLC with the acquisition of Haney/Lowderman. Wetrich recently received an appointment as a fellow at the Stanford Distinguished Careers Institute for 2015. Wetrich is also a fellow of the American College of Healthcare Executives. In 1989, he received the Outstanding Alumnus Award from Tulane University.

Wetrich recently received an appointment as a fellow at the Stanford Distinguished Careers Institute for 2015.

Wetrich is also a fellow of the American College of Healthcare Executives. In 1989, he received the Outstanding Alumnus Award from Tulane University.

Wetrich currently serves on the boards of Optomeditech, Movi Medical and Debra of America. At Emory University, he is on the Board of Visitors as well as the School of Nursing Dean's Advisory Board. Additionally, at the University of Southern California, he serves on Price School of Public Policy's Advisory Board and the Marshall School of Business' Supply Chain Institute and the Nexxspan Advisory Board, as well as, the health care advisory board of the Vistria Fund and Radius Ventures. Jim garners his talent, hard work and remarkable success to help organizations in the health care industry.


Former Employer Testimonials

Abbott Laboratories

"In 1993, Jim was responsible for launching Isoflurane, USP into the U.S. market. Jim coordinated a team that wrote the launch plan and executed the launch. In less than one month, the Hospital Products Division at Abbott captured 50 percent of the U.S. market for Isoflurane. Then General Manager, Christopher B. Begley, noted in regard to the launch that it was, 'best in recent Abbott history.' Abbott's Chief Operating Officer at the time, Thomas R. Hodgson, said that the Isoflurane launch was the 'best execution of a sales and marketing program that I have seen in my business career.'"
– Christopher B. Begley, Former General Manager, Abbott Laboratories and Thomas R. Hodgson, COO, Abbott Laboratories

Molnlycke Health Care

"[Jim] Stepped into the role as President of U.S. and Latin America Wound Care at Molnlycke Health Care and created a new company culture with sustained, outstanding performance; in eight years, growing top line over 7+ times and growing bottom line (EBITA) over 20+ times. [Jim] created one of the best teams in the med-tech industry based upon [our] sustained performance [in the United States]."
- Pierre Guyot, retired CEO of Molnlycke